The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 07, 2006
Filed:
Mar. 10, 2003
Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
Fang-yu Lee, Tachia, Taichung, TW;
Shan-chiung Chen, Fengyuan City, Taichung, TW;
Bin-ken Chen, Waipu Shiang, Taichung, TW;
Chiung-ju Tsai, Kejuang Li, Yuanli Jen, Miaoli, TW;
Yen-ling Yi, Dajia Jen,, Taichung, TW;
Wei-liang Lin, Anle Chiu, Keelung, TW;
Fang-Yu Lee, Tachia, Taichung, TW;
Shan-Chiung Chen, Fengyuan City, Taichung, TW;
Bin-Ken Chen, Waipu Shiang, Taichung, TW;
Chiung-Ju Tsai, Kejuang Li, Yuanli Jen, Miaoli, TW;
Yen-Ling Yi, Dajia Jen,, Taichung, TW;
Wei-Liang Lin, Anle Chiu, Keelung, TW;
Other;
Abstract
The present invention provides a topical formulation containing NSAID, particularly diclofenac. The topical formulation is particularly useful for alleviating pain/inflammation associated with infection caused by herpes virus, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV). Similar relief can be achieved where diclofenac is replaced with another non-steroidal anti-inflammatory drug (NSAID), which includes, without limitation, etodolac, ketorolac, bromfenac, diflunisal, ibuprofen, fenoprofen, ketoprofen, naproxen, suprofen, meclofenamate, mefenamic acid, piroxicam, meloxicam, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, and tolmetin. The topical formulation is further characterized by its fast relief on pain and/or inflammation associated with infection caused by herpes virus, i.e., a complete relief in no more than seven (7) days after the application of the topical formulation on skins of patients.